ライフサイエンスコーパス: pmol

1 +/- 4.4 pmol/mg) and FTICR MS (56.9 +/- 6.0 pmol/mg) did not significantly differ from those of the

2 than in healthy controls (from 0.86 to 3.00 pmol/L).

3 in) plus exendin(9-39)NH(2) (0-20 min: 1,000 pmol/kg/min; 20-240 min: 450 pmol/kg/min), B) GIP(3-30)N

4 Lu-DOTATATE, injection of 10, 200, and 2,000 pmol of (177)Lu-OPS201 did not cause any relevant tumor

5 , p = 0.499; I(2): 55.58%), fT4 (WMD: -0.003 pmol/L, 95% CI: -0.018, 0.011, p = 0.656; I(2): 87.58%)

6 ce test (MMTT) C-peptide as negative (<0.007 pmol/mL; n = 15), low (0.017-0.200; n = 16), intermediat

7 p = 1.00; n = 46,186); fasting insulin (0.01 pmol/l [95% CI -0.00, 0.01,]; p = 0.22; n = 46,186); BMI

8 profound antinociception (i.t. ED50 = 0.0146 pmol/mouse) that was 2000x greater than morphine.

9 N2 fixation rates were up to 3.02 pmol N copepod(-1) day(-1).

10 ed no significant changes in fT3 (WMD: 0.027 pmol/L, 95% CI: -0.052, 0.107, p = 0.499; I(2): 55.58%),

11 on of MG (2.27 +/- 0.21 versus 1.28 +/- 0.03 pmol/10(6) cells, P < 0.01) and formation of MG-modified

12 lucose uptake (4.4 +/- 0.55 vs. 2.6 +/- 0.04 pmol/mg/min; P <= 0.001) with enhanced AMPK activation (

13 e the minor T-allele associated with a 0.057 pmol/L higher pro-ENK level per allele (P=4.67x10(-21)).

14 metabolite (TX-M; 1.4 +/- 0.3 vs 0.9 +/- 0.1 pmol/mg Cr, P < .01) levels were higher in group II than

15 unchanged, whereas TX-M levels (0.7 +/- 0.1 pmol/mg Cr, P = .07) tended to decrease in group I.

16 oduction at the dose of 2.6 mumol/min by 1.1 pmol.min(-1).100 mL(-1) tissue (95% confidence interval,

17 als = 99), but lowered fasting insulin (-1.1 pmol/L; -1.7, -0.5; n = 90).

18 1.4 nmol EEQ/L, 76.6 pmol DHT-EQ/L, and 10.1 pmol TEQ/L, respectively.

19 RRE increased mitochondrial function by 19.1 pmol/s per milligram (CI, 7.3-30.8; P=0.002) compared wi

20 levosimendan treatment (from 252.1 +/- 31.1 pmol/l at baseline to 215.02 +/- 27.96 pmol/l at 6 h, p

21 led respiration (9.7 +/- 7.7 vs 13.7 +/- 4.1 pmol O2/s/10 cells; p = 0.02) and spare respiratory capa

22 ients and controls were 45.8 pmol/l and 45.1 pmol/l, respectively (p = 0.86).

23 ol/L (SD 2.5) to 3.4 (1.6; mean decrease 6.1 pmol/L (5.4-6.8; p<0.0001).

24 ranged from below the detection limit of <1 pmol L(-1) to 5 pmol L(-1), with average concentrations

25 nts on the level of sub-10 ng or picomole (1 pmol).

26 its of quantification and linear ranges to 1 pmol.

27 the minimum detectable concentration was ~1 pmol in contrast to ~5 nmol in the colorimetric assay.

28 6 vs. 0.7 +/- 0.6 x 10(-4) dL kg(-1) min(-1) pmol/L(-)(1) at w0 vs. w6-HFD [P < 0.05], respectively;

29 mals (1.8 +/- 0.3 x 10(-4) dL kg(-1) min(-1) pmol/L(-1) at HFD + RDN [P < 0.001] vs. w6-HFD, [P not s

30 3 vs. 0.5 +/- 0.3 x 10(-4) dL kg(-1) min(-1) pmol/L(-1) at w0 vs. w6-HFD [P < 0.001], respectively).

31 d Kd were 1.15 +/- 0.12 nM and 3.03 +/- 0.10 pmol/mg, respectively, in HEK293-hP2X7R membranes.

32 res of isolated FFAs to values in the low 10 pmol range.

33 ssessed estradiol level <= 2.72 pg/mL [<= 10 pmol/L] during neoadjuvant therapy).

34 0 pmol) versus high ( approximately 1 MBq/10 pmol) peptide amount of (177)Lu-NeoBOMB1, after which bi

35 pancreas (200 pmol, 570 vs. 265 mGy/MBq; 10 pmol, 435 vs. 1393 mGy/MBq).

36 4, 74, or 370 kBq, respectively, 100 muL, 10 pmol total peptide +/- 40 nmol Tyr(4)-BBN: for in vivo G

37 Visual limit of detection (LOD) of 10 pmol and spectroscopic LOD of 6.6 pmol/mL was achieved w

38 as 15.6 h (13.4-17.7) for (177)Lu-OPS201 (10 pmol) and 6.4 h (5.4-7.3) for (177)Lu-DOTATATE, resultin

39 terone and -4% (95% CI, -0.5% to -7%) per 10 pmol/L decrease in free testosterone.

40 as strongly increased in the liver (from 100 pmol/g to 500 pmol/g) independent of adrenals.

41 (sigma) for analytes containing at least 100 pmol of S.

42 24, and can readily detect formation of 100 pmol of PE produced from Escherichia coli membranes, Can

43 beled biomolecules (typically 50 pmol to 100 pmol) is quite challenging and often limits the possible

44 al keratinocytes, with triiodothyronine (100 pmol/L) or thyroxine (100 nmol/L).

45 t the same location in 2003-2004 (up to 1000 pmol kg(-1)).

46 an increase of APC levels from 1.44 to 8.11 pmol/L versus 1.27 to 5.62 pmol/L.

47 c Gd concentrations in SFB, from 8.27 to 112 pmol kg(-1) over the past two decades, and reach the nor

48 per ocean, a Pb concentration maxima (64-113 pmol kg(-1)) extended throughout the entire North Pacifi

49 ol/L.min compared with ISO 57,205 +/- 31,119 pmol/L.min).

50 for melatonin synthesis were 500 muM and 12 pmol/min.mg protein, respectively.

51 tion rate of 0.48 +/- 0.09 and 0.79 +/- 0.12 pmols/day for syn- and anti-DP, respectively.

52 with serum vitamin B-12 concentrations <120 pmol/L at screening.

53 n B-12 group (mean +/- SD change: 81 +/- 135 pmol/L for vitamin B-12 and 26 +/- 34 pmol/L for holotra

54 T in vitro (CTB: 96 +/- 16 vs SCT: 46 +/- 14 pmol O2 x min(-1) x 100 ng DNA(-1), p < 0.001) and (CTB:

55 ange: 7.0 to 19.8 pmol/l]) was elevated (>14 pmol/l) in 38% of patients.

56 Elevated NT-proBNP (>14 pmol/L), elevated high-sensitive troponin-T (>14 ng/L),

57 g N-nitrosamines ranged between 0.07 muM (14 pmol injected) and 0.13 muM (26 pmol injected).

58 surgery (173 pmol/L [129-217 pmol/L] vs 143 pmol/L [111-173 pmol/L]; p < 0.001).

59 n B-12 deficiency (plasma vitamin B-12 < 148 pmol/L or MMA > 271 nmol/L), but none were folate defici

60 y and birth weight, but B12 deficiency (<148 pmol/L) was associated with a higher risk of low birth w

61 croglia antagonists (50 nl) (PACAP(6-38), 15 pmol; minocycline 10 mg/ml) microinjected bilaterally in

62 B12 deficiency (< 150 pmol/l) in early pregnancy was 23% in cohort 1 and 18% i

63 cid > 271 nmol/L or serum vitamin B-12 < 150 pmol/L.

64 high concentrations in all dust (median 154 pmol/g) and food samples (median 0.7 pmol/g lw) but was

65 usion of sub-pathological dose of Abeta (160 pmol Abeta1-42/day i.c.v) for 14 days.

66 6- to 12-hour time point; 95% CI, -32 to 160 pmol/L).

67 pmol/L [quartile 1-3, 147-206 pmol/L] vs 160 pmol/L [131-193 pmol/L]; p = 0.039) and after cardiac su

68 2.5 x 10(-35)) and serum insulin (beta = 165 pmol l(-1), P = 1.5 x 10(-20)) 2 hours after an oral glu

69 rs compared with survivors, both before (168 pmol/L [quartile 1-3, 147-206 pmol/L] vs 160 pmol/L [131

70 ectrometry quantification showed that 32-169 pmol/mg protein of 3-deoxythreosone-derived hydroimidazo

71 using a standard suppressor, permitting 3-17 pmol LODs on 2 mm bore columns.

72 the placebo group (-27 +/- 64 and -5 +/- 17 pmol/L, respectively) after adjustment for baseline conc

73 e placebo group (0.06 [0.16] vs -0.04 [0.17] pmol/L) (P = .04).

74 concentrations were 210 pmol/L (61) and 172 pmol/L (49), respectively.

75 ol/L [129-217 pmol/L] vs 143 pmol/L [111-173 pmol/L]; p < 0.001).

76 (3.47-13.9 nmol/L, or free testosterone <173 pmol/L) were randomly assigned (1:1), via computer-gener

77 ]; p = 0.039) and after cardiac surgery (173 pmol/L [129-217 pmol/L] vs 143 pmol/L [111-173 pmol/L];

78 ict hospital mortality was approximately 175 pmol/L, and higher levels were associated with mortality

79 SEM; incremental AUCinsulin 11,000 +/- 1800 pmol/L .min compared with 18,700 +/- 3100 pmol/L .min, P

80 1-3, 147-206 pmol/L] vs 160 pmol/L [131-193 pmol/L]; p = 0.039) and after cardiac surgery (173 pmol/

81 (threshold limit 0.10 x 10(-3) U, i.e., 0.2 pmol), and C1Inh function was quantified in the sample,

82 glucose uptake (3.2 +/- 0.3 vs. 2.3 +/- 0.2 pmol/mg/min; P <= 0.001).

83 eosone-derived hydroimidazolone and 1.1-11.2 pmol/mg protein of 3-deoxythreosone-derived hydroimidazo

84 n of the substrate occurred at a rate of 2.2 pmol min(-1) mg(-1) and was also effectively inhibited b

85 d proteins (24.0 +/- 3.7 versus 14.1 +/- 3.2 pmol/10(6) cells/day; P < 0.001).

86 oxic at doses ranging from 32 fmol/kg to 3.2 pmol/kg.

87 after 90 min compared with placebo (mean 3.2 pmol/L [SD 0.86] vs 2.1 [0.65], p=0.004), increased insu

88 en had median copeptin levels of 3.0 and 5.2 pmol/L, respectively (P<0.001).

89 nstrated sensitivity down to approximately 2 pmol of S(14)NO groups and approximately 5 pmol of S(15)

90 ion from approximately 10 to approximately 2 pmol/mL and from approximately 40 to approximately 10 mu

91 s was found to be identical and was 10 nM (2 pmol), similar to analogous QD-FRET using labeled oligon

92 The limit of detection (LOD) was 2 pmol.

93 doses (specific activities) of less than 20 pmol (>1,000 MBq/nmol) and 1 nmol (20 MBq/nmol) per mous

94 When less than 20 pmol was applied, high uptake of (68)Ga-aquibeprin in th

95 The reduction was similar for 10 and 200 pmol, whereas lysine performed better than succinylated

96 In HeLa cells, at 200 pmol ASO (with PA:LFN-GAL4), 5.4 +/- 2.0% Synt5 expressi

97 -NeoBOMB1 or a low ( approximately 1 MBq/200 pmol) versus high ( approximately 1 MBq/10 pmol) peptide

98 d dose to the tumor versus the pancreas (200 pmol, 570 vs. 265 mGy/MBq; 10 pmol, 435 vs. 1393 mGy/MBq

99 proportions of subjects above/below the 200 pmol/L clinical trial eligibility threshold at the 12-mo

100 eptide mass of (177)Lu-OPS201 from 10 to 200 pmol drastically decreased the effective dose from 0.090

101 Using 200 pmol ASOs, Nucleofection(R) reduced Synt5 expression to

102 y) Synt5 expression after treatment with 200 pmol of ASO and demonstrated versatility.

103 th before (168 pmol/L [quartile 1-3, 147-206 pmol/L] vs 160 pmol/L [131-193 pmol/L]; p = 0.039) and a

104 ations of at least 27 +/- 6 mM or 104 +/- 21 pmol m(-3).

105 (serum vitamin B-12 concentrations: 107-210 pmol/L) in the absence of anemia and received 1 mg cryst

106 of hydrogen peroxide (4 pmol for CL and 210 pmol for amperometry) and zeptomoles of HRP (45 zmol for

107 vitamin B-12 concentrations >/=107 and <210 pmol/L without anemia, n = 201).

108 nd free testosterone concentrations were 210 pmol/L (61) and 172 pmol/L (49), respectively.

109 d after cardiac surgery (173 pmol/L [129-217 pmol/L] vs 143 pmol/L [111-173 pmol/L]; p < 0.001).

110 rate (mean +/- SEM, 107 +/- 8 vs. 235 +/- 22 pmol/min/30,000 cells; P < 0.001), produced more superox

111 luble activities of 151 +/- 20 and 36 +/- 22 pmol/min/mug, respectively.

112 oltage-gated calcium channel antibodies (220 pmol/L).

113 stosterone concentrations increased from 222 pmol/L (62) to 364 pmol/L (222).

114 hange in C-peptide area under curve was -229 pmol/L (95% CI -316 to -142) for the treatment group and

115 had lower NT-proANP levels (1427 versus 2291 pmol/L; P<0.001) and higher diastolic blood pressures (7

116 ation of vitamin B-12 (641 compared with 231 pmol/L), a 331% increase in serum holotranscobalamin (24

117 ive: 613(300-1090); DSA positive 106(34-235) pmol/L [p = 0.004]).

118 vel (0.86 to 1.90 ng per deciliter [11 to 24 pmol per liter]), and for hypothyroxinemia, defined as a

119 ntly, one intravitreal injection (IVI) of 25 pmol MTX increased electroretinogram (ERG) response and

120 Single topical administration of 25 pmol of 12 increased tear volume in wild-type mice with

121 r thousand for OSCs at a concentration of 25 pmol or 1.4 ppm, and better than 0.5 per thousand for co

122 ICV administration of 0.5 ul of 50 uM (25 pmol, 14.6 ng) ouabain into each lateral brain ventricle

123 Injection of approximately 250 pmol (68)Ga-NeoBOMB1 resulted in a tumor and pancreas up

124 njected with either approximately 13 MBq/250 pmol (68)Ga-NeoBOMB1 or a low ( approximately 1 MBq/200

125 ridinoline cross-link concentration of >2500 pmols g(-1) dry mass.

126 of eligible candidates, with C-peptide >252 pmol/L emerging as the best prognostic factor.

127 16 to -142) for the treatment group and -253 pmol/L (-383 to -123) for the placebo group; this differ

128 (minimum-maximum) insulin concentration (254 pmol/L [88-797 pmol/L]), and median C-peptide concentrat

129 0.07 muM (14 pmol injected) and 0.13 muM (26 pmol injected).

130 -dietary oil [3293 +/- 404 and 1674 +/- 270 (pmol/L) x 120 min; P = 0.002].

131 The limits of detection range from 7 to 278 pmol.

132 mmol/L (SD 0.66), mean fasting insulin 71.29 pmol/L (47.72), and mean HOMA2-IR 1.35 (0.91).

133 when added to clinical scores; levels <133.3 pmol/l and >211.3 pmol/l detected low-risk and high-risk

134 acebo (-205.6 pmol/L; 95% CI: -255.8, -155.3 pmol/L).

135 f E2 for all male subjects was 50.1 +/- 16.3 pmol/L, significantly higher compared to 13.8 +/- 11.8 p

136 ; n = 23), 2 h post-challenge insulin (-20.3 pmol/L; -32.2, -8.4; n = 11), and homeostasis model asse

137 ical scores; levels <133.3 pmol/l and >211.3 pmol/l detected low-risk and high-risk patients, respect

138 ble groups was determined to be 30.0 +/- 3.3 pmol.cm(-2), and copper-mediated azide-alkyne cycloaddit

139 36.0 nmol/L), higher PTH (median 7.7 vs 3.3 pmol/L) and similar calcium concentrations compared to W

140 kers, NT-proBNP in the upper quartile (>33.3 pmol/L) was most strongly associated with cardiovascular

141 PENK levels <48.3 pmol/l and >91 pmol/l detected low- and high-risk patien

142 992 +/- 1340, 14.1 +/- 4.9, and 66.1 +/- 7.3 pmol min(-1) mg protein(-1) in beta-TBECH.

143 odestly increased GLP-1 ( approximately 5-30 pmol/L).

144 that no loss of antisense activity above 30 pmol ASO was evident.

145 Vasopressin (3, 10, and 30 pmol/kg, IV) produced increased reduction in renal blood

146 oaspartyl residues in yeast proteins (50-300 pmol of isoaspartyl residues/mg of protein extract) is c

147 kidney 293 (HEK) (Km 3.8 microM and Vmax 307 pmol/mg per minute) and HeLa (Km 0.32 microM and Vmax 42

148 00 pmol/L .min compared with 18,700 +/- 3100 pmol/L .min, P = 0.018).

149 NR (4558 +/- 749 compared with 3025 +/- 316 pmol/mg dry weight in NR and placebo, respectively; chan

150 ents, achieving a limit of detection of 0.32 pmol.

151 or iron deficiency (ferritin <15 ng/mL or 32 pmol/L), vitamin A deficiency (retinol-binding protein <

152 * min(-1) * m(-2) * mM(-1) vs. 44 [IQR, 32] pmol * min(-1) * m(-2) * mM(-1), P < 0.0001), and insuli

153 limit of detection from 10 nmol L(-1) to 320 pmol L(-1) streptavidin concentration with a much higher

154 /- 135 pmol/L for vitamin B-12 and 26 +/- 34 pmol/L for holotranscobalamin) than in the placebo group

155 sensitivity increased (median, 55 [IQR, 35] pmol * min(-1) * m(-2) * mM(-1) and 55 [IQR, 39] pmol *

156 hosphorylation rates ranging from 0.34 to 36 pmol min(-1) mg(-1) (n = 6).

157 ations increased from 222 pmol/L (62) to 364 pmol/L (222).

158 (>1000 m) Pb concentrations were lower (6-37 pmol kg(-1)), and constituted a mix of background (natur

159 mg/dL, and fasting insulin concentration 37 pmol/L) were used.

160 ting plasma insulin concentrations (MD: 3.38 pmol/L; 95% CI: 0.03, 6.73 pmol/L; P < 0.05) and induced

161 and saturable binding capacity (Bmax), 6.38 pmol/mg protein.

162 4+/-0.42 pmol per milliliter vs. 0.43+/-0.39 pmol per milliliter, P<0.001).

163 -0.02 mmol/L (95% CI: -0.09, 0.05) and -2.39 pmol/L (95% CI: -11.83, 7.05), respectively.

164 * min(-1) * m(-2) * mM(-1) and 55 [IQR, 39] pmol * min(-1) * m(-2) * mM(-1) vs. 44 [IQR, 32] pmol *

165 ts, Bavail, appKD, and ED50 were 3.9 +/- 0.4 pmol/mL, 2.2 +/- 0.4 nM, and 12.0 +/- 2.6 nmol/kg, respe

166 least 20%, with a limit of detection of 2.4 pmol.

167 rain concentrations for TOF MS (51.1 +/- 4.4 pmol/mg) and FTICR MS (56.9 +/- 6.0 pmol/mg) did not sig

168 as down to picomoles of hydrogen peroxide (4 pmol for CL and 210 pmol for amperometry) and zeptomoles

169 d in both sidestream (8.05 +/- 1.32) x 10(4) pmol/g and mainstream TPM (7.41 +/- 0.85) x 10(4) pmol/g

170 g and mainstream TPM (7.41 +/- 0.85) x 10(4) pmol/g of conventional cigarettes.

171 erminal pro-B-type natriuretic peptide) >=40 pmol/L and among participants with underlying >=24-hour

172 r c-di-GMP levels of biofilm cells to </= 40 pmol mg(-1) correlated with increased susceptibility and

173 pmol/L .min compared with 68,100 +/- 11,400 pmol/L .min, P = 0.003) and 41% lower in subjects with T

174 ented concentrations ( approximately 300-400 pmol/L), drastically reducing glucose in Gipr null and L

175 characterized by 3DCC was approximately 400 pmol (836 ng).

176 SEM; incremental AUCinsulin 31,900 +/- 4100 pmol/L .min compared with 68,100 +/- 11,400 pmol/L .min,

177 mab group and the placebo group (0.64+/-0.42 pmol per milliliter vs. 0.43+/-0.39 pmol per milliliter,

178 minute) and HeLa (Km 0.32 microM and Vmax 42 pmol/mg per minute) cells.

179 the injection sites ranged from 371 to 1,441 pmol, which represented 16.5%-64.1% of the injected dose

180 creased to 43.7 +/- 8.02% on injection of 45 pmol/fly of BruIB.

181 The injection of 45 pmol/fly of each toxin dramatically decreases the respon

182 0-20 min: 1,000 pmol/kg/min; 20-240 min: 450 pmol/kg/min), B) GIP(3-30)NH(2), C) exendin(9-39)NH(2),

183 from 0.10 to 33.7 pmol L(-1) (median = 1.47 pmol L(-1), n = 974) and were highest in regions with a

184 ntation lowered fasting insulin (WMD: -13.47 pmol/L; 95% CI: -21.41, -5.53 pmol/L; P < 0.001) and HOM

185 ensity obtained after immobilisation was 480 pmol/muL.

186 ffer between trials (HYPER 55,850 +/- 36,488 pmol/L.min compared with ISO 57,205 +/- 31,119 pmol/L.mi

187 alytes were 1.8, 1.0, 0.8, 2.2, 0.6, and 0.5 pmol, respectively, which correspond to LLOQs of 6, 3, 3

188 fusions of GIP (1.5 pmol/kg/min), GLP-1 (0.5 pmol/kg/min), or saline (NaCl).

189 ly improved insulin secretion capacity (+0.5 pmol/L/min; 0.2, 0.8) whether replacing carbohydrate, SF

190 cebo, combined with 2) infusions of GIP (1.5 pmol/kg/min), GLP-1 (0.5 pmol/kg/min), or saline (NaCl).

191 lerian hormone concentration of at least 1.5 pmol/L.

192 Radish microgreens in bags of 29.5 pmol s(-1) m(-2) Pa(-1) oxygen transmission rate (OTR) m

193 was also higher in patients at baseline (8.5 pmol/L [6.5-12.9] vs 4.6 pmol/L [3.5-5.5]), but the area

194 free T(4) concentrations decreased from 9.5 pmol/L (SD 2.5) to 3.4 (1.6; mean decrease 6.1 pmol/L (5

195 2 pmol of S(14)NO groups and approximately 5 pmol of S(15)NO groups for S-nitroso compounds in aqueou

196 ow the detection limit of <1 pmol L(-1) to 5 pmol L(-1), with average concentrations of between 0.5 a

197 either two 2-h hyperinsulinemic (812 +/- 50 pmol/L)-euglycemic (5 +/- 0.1 mmol/L) or hyperinsulinemi

198 0.1 mmol/L) or hyperinsulinemic (812 +/- 50 pmol/L)-hypoglycemic (2.9 +/- 0.1 mmol/L) clamps.

199 ns of "GLP-1 equivalents" ( approximately 50 pmol/L).

200 sensitive assay is less than 15 pg/mL (< 50 pmol/L).

201 y of spin-labeled biomolecules (typically 50 pmol to 100 pmol) is quite challenging and often limits

202 ithmic unit of the concentration between 500 pmol L(-1) and 10 nmol L(-1).

203 creased in the liver (from 100 pmol/g to 500 pmol/g) independent of adrenals.

204 oxide (iNOS) activity (LPS: 90.18 +/- 36.51 pmol/minute/mg protein versus LPS+HU: 16.37 +/- 4.73 pmo

205 n (WMD: -13.47 pmol/L; 95% CI: -21.41, -5.53 pmol/L; P < 0.001) and HOMA-IR (WMD: -0.57 units; 95% CI

206 feeding (392 +/- 53 compared with 326 +/- 54 pmol/L, respectively; P < 0.05).

207 rum holotranscobalamin (240 compared with 56 pmol/L), and 17% lower serum homocysteine (14.2 compared

208 7.6+/-19.75 versus RV failure, 137.8+/-11.57 pmol/[secxmL]; P=0.0004), and mitochondrial structural d

209 risk of adverse clinical outcomes (MBG>/=574 pmol/L: hazard ratio 1.58 [1.10-2.31], P=0.014) even aft

210 oth pathways were inhibited (from 3.1 to 1.6 pmol/100 blastocysts).

211 11%; -0.17, -0.05) and fasting insulin (-1.6 pmol/L; -2.8, -0.4).

212 pro-B-type natriuretic peptide (median: 11.6 pmol/l [interquartile range: 7.0 to 19.8 pmol/l]) was el

213 duced dp-ucMGP compared with placebo (-205.6 pmol/L; 95% CI: -255.8, -155.3 pmol/L).

214 ts at baseline (8.5 pmol/L [6.5-12.9] vs 4.6 pmol/L [3.5-5.5]), but the area under the curve above ba

215 kers (DeltaTnI >121.8 mug/l; DeltaMPO >422.6 pmol/l).

216 .3 +/- 0.1 mmol/L) and insulinemia (46 +/- 6 pmol/L) during day 2 exercise studies, GABA A activation

217 pmol/mg) than healthy controls (15.3 +/- 5.6 pmol/mg).

218 LOD) of 10 pmol and spectroscopic LOD of 6.6 pmol/mL was achieved within 5 min of incubation with cit

219 xtract corresponding to 1.4 nmol EEQ/L, 76.6 pmol DHT-EQ/L, and 10.1 pmol TEQ/L, respectively.

220 Despite equivalent day 2 insulin (93 +/- 6 pmol/L) and glucose levels (5.3 +/- 0.1 mmol/L), plasma

221 owever, the cerebral damage induced by the 6 pmol ET-1 (E6), Abeta and E6 + Abeta rats was not detrim

222 neuronal discharges in response to 30 and 60 pmol cholecystokinin octapeptide were significantly lowe

223 After 21 days of treatment, a high dose (60 pmol) of ET-1 (E60) alone caused the greatest increase i

224 iol was checked and returned at 16 pg/mL (61 pmol/L); postmenopausal range for sensitive assay is les

225 from 1.44 to 8.11 pmol/L versus 1.27 to 5.62 pmol/L.

226 ol, 388.1+/-23.54 versus 4HNE, 143.7+/-11.64 pmol/[secxmL]; P<0.0001).

227 ne group compared with the placebo group (64 pmol/L difference at 6- to 12-hour time point; 95% CI, -

228 he human lens at levels ranging from 0 to 64 pmol/mg lens.

229 placebo, respectively; change: 1533 +/- 683 pmol/mg dry weight, P = 0.04) and the capacity to form a

230 ian 154 pmol/g) and food samples (median 0.7 pmol/g lw) but was below detection in serum samples, sug

231 uced in the NKB antagonist group (mean 112.7 pmol/L [SD 56.0] vs 240.1 [73.6], p=0.005): in keeping w

232 s in surface waters ranged from 0.10 to 33.7 pmol L(-1) (median = 1.47 pmol L(-1), n = 974) and were

233 The limit of detection was calculated as 4.7 pmol/L.

234 rodialysis ET-1 perfusions (1, 3, 4, 5 and 7 pmol) with either lactated Ringer solution alone, or wit

235 spect to the input PCR amplicon, or up to 70 pmol per 100 mul PCR reaction.

236 GLP-1 response [583 +/- 101 and 538 +/- 71 (pmol/L) x 120 min; P = 0.733], whereas the GIP response

237 ute/mg protein versus LPS+HU: 16.37 +/- 4.73 pmol/minute/mg protein; P <0.05); 2) tumor necrosis fact

238 rations (MD: 3.38 pmol/L; 95% CI: 0.03, 6.73 pmol/L; P < 0.05) and induced hepatic insulin resistance

239 ction limits of 50 mug oxidized BSA and 0.75 pmol carbonyls.

240 ing plasma insulin concentrations (MD: -0.79 pmol/L; 95% CI: -6.41, 4.84 pmol/L; P = 0.78), the homeo

241 in FII 20210G>A carriers (from 1.03 to 5.79 pmol/L), and more in FII 20210G>A carriers (P=2x10(-4))

242 (P=0.008) in FVL carriers (from 1.39 to 7.79 pmol/L) than in FII 20210G>A carriers (from 1.03 to 5.79

243 m) insulin concentration (254 pmol/L [88-797 pmol/L]), and median C-peptide concentration (2.4 nmol/L

244 re 11.8 +/- 4, 0.6 +/- 0.1, and 10.1 +/- 0.8 pmol min(-1) mg protein(-1) in TBECH mixture and 4992 +/

245 d intravenous saline (placebo) or GLP-1 (0.8 pmol/kg min), as a continuous 24-h infusion ("prolonged"

246 reased and urinary PGD-M levels (2.2 +/- 0.8 pmol/mg Cr, P < .001) decreased on 2 months of high-dose

247 tabolite (PGD-M; 13.6 +/- 2.7 vs 7.0 +/- 0.8 pmol/mg creatinine [Cr], P < .05) and thromboxane metabo

248 gnificantly higher compared to 13.8 +/- 11.8 pmol/L for postmenopausal women.

249 ailing controls (59.5+/-14.4 and 35.5+/-12.8 pmol/mg per minute, respectively).

250 rated higher total PDE-specific (74.6+/-13.8 pmol/mg per minute) and PDE3-specific (48.2+/-15.9 pmol/

251 1.6 pmol/l [interquartile range: 7.0 to 19.8 pmol/l]) was elevated (>14 pmol/l) in 38% of patients.

252 amide (lysine) adducts in HDL (54.6 +/- 33.8 pmol/mg) than healthy controls (15.3 +/- 5.6 pmol/mg).

253 evels of RCC patients and controls were 45.8 pmol/l and 45.1 pmol/l, respectively (p = 0.86).

254 The detection limit was 7.8 pmol.

255 in seawater measured in this study (max 76.8 pmol kg(-1)) were much lower than those recorded at the

256 (2 hr 3.5 [1.5-5.7] vs. 18 hr 1.2 [0.3-2.8] pmol/mL; P=0.010).

257 <80 pmol/L: beta=-0.013, p=1.6x10(-7); >/=80 pmol/L: beta=-0.008, p=1.8x10(-2), p for interaction 0.0

258 centration above the normal range (i.e., >80 pmol/L) in patients not meeting the definition of AKI.

259 PENK was elevated (>80 pmol/L, 99th percentile) in 1245 (57%) patients.

260 those with lower fasting insulin levels (<80 pmol/L: beta=-0.013, p=1.6x10(-7); >/=80 pmol/L: beta=-0

261 carbonate ions with a detection limit of 80 pmol L(-1) (5 ppt) and was utilized for direct determina

262 ravenous infusions of A) GIP(3-30)NH(2) (800 pmol/kg/min) plus exendin(9-39)NH(2) (0-20 min: 1,000 pm

263 e proposed biosensor presented a LOD of 0.82 pmol L(-1), with a linear range of 1.0 x10(-12) - 1.0 x1

264 tions (MD: -0.79 pmol/L; 95% CI: -6.41, 4.84 pmol/L; P = 0.78), the homeostasis model assessment of i

265 patients, with a starting median ARR of 8583 pmol/L per microg/(L . h) that normalized to 97 pmol/L p

266 of dye within the SLNs ranged from 8.5 to 88 pmol, which was equivalent to 0.38%-3.91% of the adminis

267 ncreased aldosterone secretion from mean 0.9 pmol/mug protein (SE 0.2) to 1.1 (0.1), whereas CYP11B2

268 g per minute) and PDE3-specific (48.2+/-15.9 pmol/mg per minute) activities in comparison with those

269 ased dramatically in group II (61.3 +/- 19.9 pmol/mg Cr, P < .05), whereas TX-M levels did not change

270 verage concentrations of between 0.5 and 2.9 pmol L(-1).

271 ) condition at a nitrosylation level of 25.9 pmol mg(-1) and the statistical significance given of P

272 ross-validated LC-MS/MS method (55.0 +/- 4.9 pmol/mg).

273 We also record 271.6-474.9 pmol/mg of Environmental Protection Agency-priority poly

274 PENK levels <48.3 pmol/l and >91 pmol/l detected low- and high-risk patients, respectivel

275 et Icmt, with K(m) (6.6 muM) and V(max) (947 pmol min(-1) mg(-1)) values comparable or better than a-

276 The median 6-TGN and TPMT levels were 953 pmol/8 x 10(5) RBC (IQR 145-1761) and 47 mu/L (IQR 34.5-

277 31.1 pmol/l at baseline to 215.02 +/- 27.96 pmol/l at 6 h, p < 0.05).

278 l/L per microg/(L . h) that normalized to 97 pmol/L per microg/(L . h) (P < .01).

279 mol with the RSD lower than 5.70 % (n = 5 at pmol level).

280 cules within the concentration range between pmol and amol.

281 suscitation resulted in higher OXPHOSCI+CII (pmol oxygen/s x mg/citrate synthase) in the cortex (6.00

282 or potential confounders, cord blood log(FT3)pmol/L concentration was 0.11 lower in newborns of mothe

283 ) -0.08, -0.02] lower maternal serum log(FT4)pmol/L, whereas the medium TCS concentration was associa

284 mbinant cytoplasmic domain of BRI1 generates pmol amounts of cGMP per mug protein with a preference f

285 0.01) lower log-transformed fasting insulin (pmol/L) and 21% lower odds (95% confidence interval, 3-3

286 Monthly erythrocyte TGN levels (pmol/8 x 108 erythrocytes) were measured over 6 consecut

287 fasting glucose concentration and a 0.049-ln-pmol/L (95% CI: 0.035, 0.063-ln-pmol/L) higher fasting i

288 d a 0.049-ln-pmol/L (95% CI: 0.035, 0.063-ln-pmol/L) higher fasting insulin concentration.

289 (APLI) with limits of detection in the lower pmol range.

290 23 +/- 25 [GLP-1] vs. 17 +/- 46 [saline] min pmol/L, P < 0.03) and endogenous glucose production was

291 2 + Trp: 229 +/- 22) and GLP-1 (AUC0-90 min, pmol/L*min; control: 102 +/- 41; C12: 522 +/- 102; Trp:

292 asma CCK (AUC(area under the curve)0-90 min, pmol/L*min; control: 21 +/- 8; C12: 129 +/- 15; Trp: 97

293 adrenocorticotropic hormone ratio <3.0 (nmol/pmol).

294 nM and intrinsic clearance = 90 mul/min per pmol).

295 m levels reached 14 parts per trillion (ppt, pmol mol(-1); 4.2 x 10(8) atoms per cm(-3)) and were up

296 State III mitochondrial respiration rates (pmol O2/s/mg wet weight) were 15.05 +/- 3.92 and 11.42 +

297 p < 0.05) and higher complex I respiration (pmol oxygen/s x mg) in the right (20.62 +/- 1.06 vs 15.8

298 Ten pmol/L GLP-1 increased both the spontaneous inhibitory p

299 droxy-2'-deoxyguanosine (8-OHdG) down to the pmol/L level.

300 d as E2 greater than 10 pg/mL (to convert to pmol/L, multiply by 3.671) and at least 10 pg/mL above b